Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP001407

Drug Information
NameNalmefene
SynonymsNalmefeno; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol; UNII-TOV02TDP9I; MLS000069366; nalmefene; NIH-10365; Cessal; D05111; Nalmetreno; Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, (5alpha)-; Nalmetreno [INN-Spanish]; Nalmefeno [INN-Spanish]; MolPort-003-959-014; Nalmetrenum [INN-Latin]; Alcofene; Nalmefene [USAN:BAN:INN]; NCGC00021666-03; ORF-11676; CID5284594; 58895-64-0 (hydrochloride); LS-91713; Soberal; C08027; Nalmefene (USAN/INN); Nalmefenum [INN-Latin]; ORF 11676; Arthene; Cervene; Revex; 6-Desoxy-6-methylenenaltrexone; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinon-3,14-diol; 55096-26-9; SMR000058884; HSDB 6761; Incystene; JF 1; N5770_SIGMA; Nalmefenum; 9a-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylen-3,14-morphinandiol; CHEBI:200696; PDSP2_001543; Nalmetrene; CHEMBL982; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol; Nalmetrenum; (5alpha)-17-(cyclopropylmethyl)-6-methylidene-4,5-epoxymorphinan-3,14-diol; JF-1
Trade NameRevex
IndicationAlcohol dependence
[ICD9: 303   ICD10: F10.2]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19
(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/
t16-,19+,20+,21-/m1/s1
InChIKeyWJBLNOPPDWQMCH-MBPVOVBZSA-N
Canonical SMILESC=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O    
Isomeric SMILESC=C1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O
Therapeutic ClassAnti-craving Agents
CAS NumberCAS 55096-26-9
FormulaC21H25NO3
PubChem Compound IDCID 5284594.
PubChem Substance IDSID 10227.
SuperDrug ATC IDN07BB05
TargetOpioid receptorAntagonist[2][3]
Ref 1Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43. To Reference
Ref 2Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther. 2009 Feb;328(2):588-97. Epub 2008 Nov 10. To Reference
Ref 3Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res. 2008 Jul;32(7):1159-66. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543